US20100022643A2 - Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers - Google Patents

Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers Download PDF

Info

Publication number
US20100022643A2
US20100022643A2 US12/465,069 US46506909A US2010022643A2 US 20100022643 A2 US20100022643 A2 US 20100022643A2 US 46506909 A US46506909 A US 46506909A US 2010022643 A2 US2010022643 A2 US 2010022643A2
Authority
US
United States
Prior art keywords
compound
amino acid
alkyl
ghb
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US12/465,069
Other versions
US20090215890A1 (en
US8778301B2 (en
Inventor
Mortimer Mamelak
William Houghton
Dayton Reardan
Brian Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jazz Pharmaceuticals Inc
Original Assignee
Orphan Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US12/465,069 priority Critical patent/US8778301B2/en
Application filed by Orphan Medical Inc filed Critical Orphan Medical Inc
Publication of US20090215890A1 publication Critical patent/US20090215890A1/en
Publication of US20100022643A2 publication Critical patent/US20100022643A2/en
Assigned to SILICON VALLEY BANK reassignment SILICON VALLEY BANK SECURITY AGREEMENT Assignors: JPI COMMERCIAL, LLC
Assigned to JPI COMMERCIAL, LLC reassignment JPI COMMERCIAL, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SILICON VALLEY BANK
Priority to US13/897,748 priority patent/US20130324759A1/en
Publication of US8778301B2 publication Critical patent/US8778301B2/en
Application granted granted Critical
Assigned to Jazz Pharmaceuticals, Inc. reassignment Jazz Pharmaceuticals, Inc. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ORPHAN MEDICAL, LLC
Assigned to Jazz Pharmaceuticals, Inc. reassignment Jazz Pharmaceuticals, Inc. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: JPI COMMERCIAL, LLC
Assigned to U.S. BANK NATIONAL ASSOCIATION reassignment U.S. BANK NATIONAL ASSOCIATION SECURITY AGREEMENT Assignors: CAVION, INC., CELATOR PHARMACEUTICALS, INC., JAZZ PHARMACEUTICALS IRELAND LIMITED, Jazz Pharmaceuticals, Inc.
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/675—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/24—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/49—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms

Definitions

  • GHB Gamma-hydroxybutyric acid or “gamma-hydroxybutyrate”
  • GHB is an endogenous compound with hypnotic properties that is found in many human body tissues.
  • GHB is present, for example, in the mammalian brain, the human nervous system and other tissues.
  • the extraordinary range of the pharmacological effects of GHB or its salts has attracted scientific attention for more than three decades.
  • GHB has been found to have tissue-protective effects in animals and man in many different organs including brain, liver, lung, heart, kidney, gut and pancreatic B cells.
  • brain the highest GHB concentration is found in the hypothalamus and basal ganglia and GHB is postulated to function as a neurotransmitter (Snead and Morley, 1981).
  • GHB neuropharmacologic effects include increases in brain dopamine, depression of glucose utilization but not oxygen consumption in the brain, and hypothermia. GHB is converted to succinate and then metabolized via the Krebs cycle. Clinical trials have shown that GHB increases delta sleep and improves the continuity of sleep (Ladinsky et al., 1983; Stock et al., 1973; Laborit, 1973; Lapierre et al., 1990; Yamada et al., 1967; Grove-White and Kelman, 1971; Scharf, 1985).
  • GHB monosodium salt sodium oxybate
  • GHB monosodium salt sodium oxybate
  • These low doses also can induce REM and slow wave sleep and, in contrast to the hypnotics in common use, without the development of tolerance to these sleep-inducing effects in time.
  • GHB increases total sleep time and REM sleep, and it decreases REM latency (Mamelak et al., 1973; Yamada et al., 1967; Bedard et al., 1989), reduces sleep apnea (Series et al., 1992; Scrima et al., 1987), and improves general anesthesia (Hasenbos and Gielen, 1985).
  • GHB has several clinical applications other than the treatment of sleep disorders. GHB has been reported to reduce alcohol craving, the number of daily drinks consumed, and the symptoms of alcohol withdrawal in patients (Gallimberti et al., 1989; Gallimberti et al., 1992; Gessa et al., 1992). GHB has been used to decrease the symptoms of opiate withdrawal, including both heroin and methadone withdrawal (Gallimberti et al., 1994; Gallimberti et al., 1993). It has analgesic effects that make it suitable as a pain reliever (U.S. Pat. No. 4,393,236). Intravenous administration of GHB has been reported to reduce intracranial pressure in patients (Strong, A. 1984).
  • GHB is also an effective therapeutic agent for the treatment of chronic fatigue syndrome and fibromyalgia (Scharf, U.S. Pat. No. 5,990,162).
  • GHB glycogen deacetylase
  • the present invention provides a compound of formula (I): wherein Y is H or a hydroxyl-protecting group, X is the residue of a carbohydrate and n has a value of 1 to the number of available hydroxyl groups in said carbohydrate, or a pharmaceutically acceptable salt thereof.
  • X is a saccharide
  • Y is H, a (C 4 -C 6 )acetal, (C 1 -C 5 )acyl or (C 1 -C 5 )alkyl.
  • Preferred carbohydrates are water-soluble or water-dispersible.
  • X is the residue of a monosaccharide, the residue of a disaccharide or the residue of a polysaccharide.
  • the monosaccharide, disaccharide or polysaccharide can contain at least one CHOH—CHOH residue that is protected as an acetal or ketal.
  • Examples of compounds of formula (I) include 1,2,3,4,6-pentakis(4-hydroxy-butyroyl)hexanose; 6-(4-hydroxy-butyroyl)hexanose and 1,2,3,4,6-pentakis(4-acetoxybutyroyl)hexanose.
  • X is the residue of a chemically-modified cellulose.
  • chemically-modified cellulose compositions include water-soluble or water-dispersible celluloses such as hydroxypropyl-methylcellulose, hydroxypropylcellulose or hydroxyethylcellulose.
  • a compound of formula (II) (R 1 O(CH 2 ) 3 CO 2 ) m (ROC(O)(CH 2 ) 3 C(O)) q —(X)—(Y) n -(Z) n -(CO 2 (CH 2 ) 3 CO 2 R) p (O 2 C(CH 2 ) 3 OR′) k (II) wherein R′ is H or a hydroxyl protecting group, R′ is H, (C 1 -C 4 )alkyl or benzyl, X and Z are each residues of a hydroxy group-containing amino acid or a bis(carboxy)amino acid, Y is a moiety covalently linking X and Z, n is 0-1, m and k are 0 to the number of available OH groups is X and Z, q and p are 0 to the number of available CO 2 groups on X and Z, with the proviso that m and q are not both
  • An embodiment of the compound of formula II is a compound of formula (III): wherein R 1 is H or a hydroxyl-protecting group, R is H, (C 1 -C 4 ) alkyl or benzyl, X is a residue of a hydroxy group-containing amino acids, Z is a residue of a hydroxy group-containing amino acid or a bis(carboxy)amino acid, Y is a moiety covalently linking X and Z, n is 0-1, m is 1 to the number of hydroxy groups on amino acid X, p is 1 to the number of CO 2 H groups on the amino acid X or Z, or a pharmaceutically acceptable salt thereof.
  • m, p, q and k are individually 0-5, more preferably 0-3, and most preferably 0-2.
  • n O
  • X glutamic acid, tyrosine, aspartic acid, threonine, or a serine.
  • n 1
  • Y is C(O)CH 2 CH 2 C(O) or C(O)CH ⁇ CH(CO).
  • the present invention also provides a compound of formula (IV): wherein L and L′ are individually H, (C 1 -C 6 )alkyl or a hydroxyl protecting group or an organic moiety comprising at least one fatty alcohol, ester or analog thereof. At least one of L and L′ is said moiety (the FA moiety).
  • the FA moiety is (A)(Y)(Z) n , and wherein A is (C 2 -C 6 )alkyl, Y is H, OH, N(R 1 )(R 2 )(R 3 ) or [—O(PO 3 ⁇ )-L-N(R 1 )(R 2 )(R 3 )] wherein R 1 , R 2 and R 3 are each (C 1 -C 4 )alkyl or R 1 and R 2 together with N are a (C 5 -C 7 )heterocyclic ring, optionally substituted with 1 or 2 N(R 3 ), S, non-peroxide O or a combination thereof; n is 1-2 and Z is YR, wherein Y is O, S, NH, N(CH 3 ), NHC(O) or OC(O) and R is (C 8 -C 22 )alkyl, optionally substituted with 1-2 double bonds.
  • L′ is a 2-substituted lecithin moiety, i.e., the C 2 OC(O)R 2 moiety of lecithin is replaced by C 2 C(O)(CH 2 ) 3 OL and Y is hexadecanoyl; L is not H.
  • L or L′ is 1,3-dihexdecanoylprop-2-yl, the other is not H.
  • L and L′ are derived from organic polyols, such as glycerol, ethylene glycol, propylene glycol, 2,2′-hydroxyethyl ether and the like.
  • the organic moieties L and L′ can also be simple fatty acid esters of C 4 —OH or fatty alcohol esters of CO 2 H.
  • the present invention also provides compounds of formula (V): wherein L is defined above, n is 2-6, preferably 2-5, most preferably 2-3, and L′′ is (C 2 -C 12 ) alkyl, preferably (C 3 -C 10 )alkyl, most preferably (C 3 -C 6 )alkyl, wherein the alkyl chain is optionally interrupted by about 1-3-O-moieties, i.e., is the residue of an alkylene polyol, preferably a 1, ⁇ -alkylene diol such as 1,3-propane diol, or a polyoxyalkylene glycol.
  • Examples of compounds of formula (V) include 1,2,3-tris(4-hydroxy-butyroyoxyl)propane and 1,3-bis(4-acetoxybutyroyoxyl)propane.
  • the present invention also provides a pharmaceutical composition comprising an effective amount of the compound of formula (I), (II), (III) or (IV), or mixtures thereof in combination with a pharmaceutically acceptable carrier.
  • the pharmaceutical composition of the present invention may be adapted for parenteral, oral, topical or local administration.
  • the present invention also provides a therapeutic method comprising administering to a mammal afflicted with a pathology or condition ameliorated by GHB, an amount of a compound of formula I, II, III, IV and/or V effective to treat said pathology or condition.
  • the term “effective amount” means that the composition can deliver an amount of GHB to a target cell, tissue or organ effective to accomplish a therapeutic objective, i.e., to alter cellular metabolism or energetics or to ameliorate at least one symptom of one of the pathologies discussed herein.
  • FIG. 1A shows a compound comprising the GHB pentaester of a fully charged hexopyranose.
  • FIG. 1B shows GHB triesters of partially charged hexopyranoses.
  • FIG. 2 shows a GHB-sucrose ester
  • FIG. 3 shows a GHB linked to representative amino acids.
  • FIG. 4 shows a GHB linked to amino acid conjugates.
  • amino acid comprises the residues of the natural amino acids (e.g. Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Hyl, Hyp, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, and Val) in D or L form, as well as unnatural amino acids (e.g.
  • the term also comprises natural and unnatural amino acids bearing a conventional amino protecting group (e.g.
  • acetyl or benzyloxycarbonyl as well as natural and unnatural amino acids protected at the carboxy terminus (e.g. as a (C 1 -C 6 )alkyl, phenyl or benzyl ester or amide; or as an ⁇ -methylbenzyl amide).
  • suitable amino and carboxy protecting groups are known to those skilled in the art (See for example, T. W. Greene, Protecting Groups In Organic Synthesis ; Wiley: New York, 1981, and references cited therein).
  • An amino acid can be linked to the remainder of a compound of formula I through the carboxy terminus, the amino terminus, or through any other convenient point of attachment, such as, for example, through the sulfur of cysteine.
  • hydroxy amino acid includes naturally occurring, synthetic and semi-synthetic amino acids, such as serine, threonine, tyrosine and hydroxyproline.
  • amino acids are ⁇ -amino acids, most preferably with ⁇ -hydroxyl groups.
  • carbohydrate as used herein is defined to include polyhydroxy aldehydes, or polyhydroxy ketones or substances that yield such compounds on hydrolysis.
  • carbohydrate includes monosaccharides, oligosaccharides, disaccharides, trisaccharides, tetrasaccharides, pentasaccharides, hexasaccharides, polysaccharides, homopolysaccharides, and heteropolysaccharides.
  • the term includes any of the aldoses, as well as glucose, dextrose, mannose, galactose arabinose, xylose, ribose, fructose, sucrose, altrose, allose, idose, gulose, talose, lyxose, threose, erythrose, apiose, and any of the same in acid form.
  • the term also includes deoxy sugars and deoxy-aldoses, including rhamnose and fucose.
  • the term further includes glyceraldehyde, cellulose, starch, glycogen, and amylose.
  • carbohydrate derivatives such as acetals, ketals, acyl esters and the like.
  • saccharide includes monosaccharides, disaccharides, trisaccharides and polysaccharides.
  • the term includes glucose, sucrose, fructose and ribose, as well as deoxy sugars such as deoxyribose and the like. Saccharide derivatives can conveniently be prepared as described in International Patent Applications Publication Numbers WO 96/34005 and 97/03995.
  • oligopeptide describes a sequence of 2 to 25 amino acids (e.g. as defined hereinabove) or peptidyl residues.
  • the sequence may be linear, branched or cyclic.
  • a cyclic peptide can be prepared or may result from the formation of disulfide bridges between two cysteine residues in a sequence.
  • An oligopeptide can be linked to the remainder of a compound of formula I through the carboxy terminus, the amino terminus, or through any other convenient point of attachment, such as, for example, through the sulfur of a cysteine.
  • a peptide comprises 3 to 25, or 5 to 21 amino acids.
  • Peptide derivatives can be prepared as disclosed in U.S. Pat. Nos. 4,612,302; 4,853,371; and 4,684,620.
  • linking moiety refers to an at least divalent organic molecule that can join two amino acids or oligopeptidyl residues by reaction with functional groups therein.
  • moieties include alkane and alkene dicarboxylic acids and diamines.
  • alkyl includes branched, straight-chain and cyclic alkyl groups, including (cycloalkyl)alkyl.
  • a fatty alcohol is a (C 8 -C 22 )alkanol, preferably a (C 10 -C 20 )alkanol, optionally comprising 1-3 double bonds;
  • a fatty acid is a (C 8 -C 22 )alkanoic acid (i.e., (C 1 -C 11 )C(O)OH), optionally comprising 1-3 double bonds.
  • hydroxyl protecting group includes removable hydroxy moiety protecting groups known to the art, such as acid- or base-labile groups such as acetals (THP, (1-ethoxy)ethyl), tris(alkyl)silyl groups (Me 3 , Si, (t-Bu(Me 2 )Si)), (C 2 -C 7 )acyl groups (acetyl), as well as groups that can be removed by hydrogenolysis, such as benzyl. See, also, part (C)(a), hereinbelow, which references additional OH protecting groups.
  • acid- or base-labile groups such as acetals (THP, (1-ethoxy)ethyl), tris(alkyl)silyl groups (Me 3 , Si, (t-Bu(Me 2 )Si)), (C 2 -C 7 )acyl groups (acetyl), as well as groups that can be removed by hydrogenolysis, such as benzyl. See, also, part (C)
  • GHB has been shown to be effective in treating narcolepsy and sleep disorders (Lee, 1977; Mamelak, 1977; Hoes, 1980; Scharf, 1985; Scrima, 1990; Gallimberti, 1992; Series, 1992; Lammers, 1993), reducing alcohol craving and alcohol withdrawal symptoms (Gallimberti et al., 1989; Gallimberti et al., 1992; Gessa et al., 1992), reducing opiate withdrawal symptoms (Gallimberti et al., 1994; Gallimberti et al., 1993), reducing pain (U.S. Pat. No.
  • GHB has been used with other analgesics, neuroleptics, or with a subliminal barbiturate dose for use as an anesthesia.
  • GHB has been used in closed cranio-cerebral trauma and as soporifics (U.S. Pat. No. 5,380,937). Therefore, the compounds of the present invention can also be used in combination with analgesics, neuroleptics or barbiturates for use as an anesthesia.
  • the inventors contemplate the use of the GHB compositions of the present invention as a narcotic, hypnotic, or as a soporific.
  • the present invention provides compounds and pharmaceutical compositions that can be used in the treatments of hypnosis; narcolepsy (particularly cataplexy); drug abuse; anxiety; cerebrovascular diseases; central nervous system disorders, neurological disorders, including Parkinson's Disease and Alzheimer Disease; Multiple Sclerosis; autism; depression; inflammatory disorders, including those of the bowel, such as irritable bowel disorder, regional illitis, and ulcerative collitis; autoimmune inflammatory disorders; certain endocrine disturbances and diabetes.
  • the present compounds can also be administered for the purpose of tissue protection, including protection following hypoxia/anoxia such as in stroke, organ transplantation, organ preservation, myocardial infarction or ischemia/reperfusion injury; protection following radiation, progeria, or an increased level of intracranial pressure, e.g., due to head trauma.
  • tissue protection including protection following hypoxia/anoxia such as in stroke, organ transplantation, organ preservation, myocardial infarction or ischemia/reperfusion injury; protection following radiation, progeria, or an increased level of intracranial pressure, e.g., due to head trauma.
  • the present compounds can be used to treat other pathologies believed to be caused or exacerbated by lipid peroxidation and/or free radicals, such as pathologies associated with oxidative stress, including normal aging.
  • GHB is available from the Aldrich Chemical Co., Milwaukee, Wis., and can be employed to prepare the compounds within the scope of formula (I) or (II).
  • the GHB compositions of the present invention can be prepared by and administered by any of the means described herein, particularly those described in the section and the examples, or by any means as would be known to those of skill in the art.
  • a compound of the present invention can be employed as the free acid or alcohol, or as a pharmaceutically acceptable salt or ester thereof.
  • Such salts can be formed from acids or amino groups described herein, by methods available to one or ordinary skill in the art. In cases where compounds are sufficiently basic or acidic to form stable salts with nontoxic organic acids or metal salts, administration of the compounds as salts may be appropriate.
  • pharmaceutically acceptable salts are organic acid addition salts formed with acids which can form a physiological acceptable anion, for example, tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate, ⁇ -ketoglutarate, and ⁇ -glycerophosphate.
  • Suitable inorganic salts may also be formed, including hydrochloride, sulfate, nitrate, bicarbonate, and carbonate salts.
  • Pharmaceutically acceptable salts may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically acceptable anion.
  • Alkali metal (for example, sodium, potassium or lithium) or alkaline earth metal (for example calcium) salts of carboxylic acids can also be made.
  • the cations can also be readily exchanged with other metal or organic cations, such as Ca + , K + , Li + , or (R) 4 N + wherein each R is H, phenyl, (C 1 -C 6 )alkyl or hydroxy(C 1 -C 6 )alkyl, i.e., ammonium or hydroxyethyl amine salts.
  • other metal or organic cations such as Ca + , K + , Li + , or (R) 4 N + wherein each R is H, phenyl, (C 1 -C 6 )alkyl or hydroxy(C 1 -C 6 )alkyl, i.e., ammonium or hydroxyethyl amine salts.
  • Hydroxy protecting groups such as esters, ethers, acetals and ketals may be utilized in the present compounds.
  • Useful hydroxy protecting groups are descried in Greene, T. W.; Wutz, P. G. M., “Protecting Groups in Organic Synthesis”, 2nd ed., John Wiley & Sons, Inc (1991).
  • GHB can be esterified with (C 1 -C 4 )alkanols or the benzyl ester prepared.
  • ester preparation methods see S. Ege, Organic Chemistry , p. 454-455, 459, 466-467 (D.C. Heath and Co., 1984). See also, Pouillart et al., Eur. J. Pharm. Sci., 7, 93-106 (1998).
  • the OH group can be protected by formation of an acetal or by alkanoylation or benzoylation with an alkanoyl or benzoyl chloride or with anhydrides.
  • Other useful acid- and base-labile hydroxy-protecting groups are described in Greene, T. W.; Wutz, P. G. M. “Protecting Groups In Organic Synthesis” second edition, 1991, New York, John Wiley & Sons, Inc.
  • the ester can be removed and the acid can be activated if necessary, i.e., by formation of an acid chloride or anhydride.
  • an acid chloride or anhydride for preparation methods for 4-hydroxy-butanoic acid and its derivatives, see, Marvel et al., J. Am. Chem. Soc., 51, 260 (1929); Japanese patent 63174947, German Pat. Nos. 237310, 237308 and 237309.
  • the activated carboxyl group of GHB can be reacted with the target hydroxyl groups in various sugars via ester bonds, as described, for example, in P. Pouillart et al., Eur. J. Pharm. Sci., 7, 93 (1998), P. R. Pouillart, Life Sciences, 63, 1739 (1998); P. Pouillart et al., J. Pharm. Sci., 81, 241 (1992), and references cited therein.
  • Most types of sugars including triose (or glycerol) tetroses, pentoses and hexoses can be used to make the compounds of the present invention.
  • the open chain and ring (pyranoses and furanoses) forms may be used as scaffolds.
  • An example of hexopyranose is depicted in FIG. 1 a , where a maximum of 5 GHB molecules can be anchored to each sugar monomer.
  • GHB compounds can be synthesized from sucrose (containing a furanose and a pyranose ring), glucose and one from any open chain hexose. These compounds may be synthesized by a single step from free GHB or from its lactone.
  • hydrocarbon chains may provide adequate protection from enzymes present in the digestive tract.
  • These compositions may be susceptible to acid catalyzed hydrolysis, which depends on the steric environments around each ester bond. For example, the 6-OH ester bond will be readily hydrolyzed.
  • These molecules may be viewed as miniature micelles and can be transported into the circulatory system via the fat absorption mechanism.
  • Linking GHB to partially charged sugars may provide for better uptake and delivery of the drug.
  • the depicted compound has only 3-GHBs attached to the sugar.
  • the choice of hydroxyl groups for esterification can be based on the rates of hydrolysis of the corresponding esters so that desired levels of free GHB can be maintained within the cells of the target organ.
  • Free hydroxyl groups can be used to anchor various groups. Steric shielding of GHB-ester linkages enhances the stability of the compounds in acidic medium. For example, one or more pairs of adjacent OH group groups on the sugar ring can be protected as acetals or as ketals, as taught by Pouillart et al., cited above, using acetals. The ketone can be varied in bulk, in order to shield the ester linkages to a greater or lesser extent. The attachment of lipophilic groups, such as steroids or fatty acids, to GHB via e.g., ketal or acetal linkages, can enhance the transfer across the blood-brain barrier.
  • lipophilic groups such as steroids or fatty acids
  • a lipophilic composition may also be useful for delivery of GHB via salves or dermal patches. Free hydroxyl groups of the sugar may also be used to attach a second complementary therapeutic agent to the GHB composition.
  • Amino acids (AA), serine, threonine, tyrosine, aspartic acid and glutamic acid contain side chains containing OH groups and/or second CO 2 H groups that can be coupled to GHB by ester linkages, following N-protection (See FIG. 3 ). Each of these compounds could be linked to two GHB molecules. Alternatively, the carboxylic acid of GHB can be reacted with an acid-protected amino acid to form the amide from the amine of the amino acid. Because the ester linkages of these compounds have different steric environments, the hydrolysis rates of these compounds in vivo will vary. A significantly slow rate of hydrolysis will be seen with serine and threonine, due to the ester linkages associated with their side chains.
  • AA-(GHB) 2 the ester linkage associated with the phenoxy side chain can be very rapidly hydrolyzed.
  • Single amino acid compounds, i.e., AA-(GHB) 2 can only deliver 2 GHB molecules, and due to the lack of steric shielding, these compounds may have limited stability in the stomach pH.
  • tailored small peptides having 3 to 5 amino acids can significantly improve the quantity of GHB delivered and have enhanced stability.
  • the compounds of the present invention may comprise two or more amino acids.
  • Such compounds can be constructed by using covalent linking moieties such as succinic acid to couple the amino acids tyrosine and threonine, or using maleic acid to couple aspartic and glutamic acids.
  • Each of these conjugates comprises 4 GHB per molecule, where each ester linkage is in a significantly different steric shielding. (See FIG. 4 ).
  • the succinic and maleic acid linkers have significantly different degrees of flexibility.
  • Succinic acid has full rotational freedom, whereas using maleic acid, GHB molecules will be held in a cis orientation.
  • Each compound, having two amide and four ester linkages can give rise to distinct structural organizations with different stability and cellular uptake.
  • the compounds of formula III can be prepared as disclosed in PCT WO 92/03462; U.S. Pat. No. 5,223,263; PCT/US91/04289; or PCT/US94/05855.
  • Lecithin or a sphingolipid can be partially hydrolyzed to yield one or more free OH groups and GHB attached as discussed above.
  • Compounds of formula (V) can be prepared by the reaction of polyols (L′′(OH) n ) with 4-halobutyroylchloride, which is then hydrolyzed and the 4-hydroxyl group protected, or the 4-halo group is displaced by L′′O ⁇ or an equivalent thereof.
  • the invention provides a pharmaceutical formulation comprising a compound of formula (I), (II), or (III), together with one or more pharmaceutically acceptable carriers therefor and, optionally, other therapeutic and/or prophylactic ingredients.
  • the cations and carrier(s) must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof, i.e., they do not produce an adverse, allergic, or other untoward reaction when administered to an animal, or a human, at appropriate levels.
  • compositions include those suitable for oral or parenteral (including intramuscular, subcutaneous and intravenous) administration.
  • forms suitable for parenteral administration also include forms suitable for administration by inhalation or insufflation or for nasal, or topical (including buccal, rectal, vaginal, transdermal or sublingual) administration.
  • the formulations may, where appropriate, be conveniently presented in discrete unit dosage forms, by bringing the active compound into association with liquid carriers, solid matrices, semi-solid carriers, finely divided solid carriers or combinations thereof, and then, if necessary, shaping the product into the desired delivery system.
  • the active compounds of the invention may be formulated for parenteral administration, e.g., formulated for injection via intravenous, intraarterial, intramuscular, subcutaneous, intralesional, intraperitoneal or other parenteral routes.
  • parenteral administration e.g., formulated for injection via intravenous, intraarterial, intramuscular, subcutaneous, intralesional, intraperitoneal or other parenteral routes.
  • the preparation of an aqueous composition that contains a GHB agent as an active component or ingredient will be known to those of skill in the art in light of the present disclosure.
  • the pharmaceutical dosage forms suitable for injection or infusion can include sterile aqueous solutions or dispersions or sterile powders comprising the active ingredient which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions.
  • the compounds of the invention may be lyophilized for more ready formulation into a desired vehicle where appropriate.
  • the active agent can optionally be encapsulated in liposomes. In all cases, the ultimate dosage form should be sterile, fluid and stable under the conditions of manufacture and storage.
  • the liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, glycerol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof.
  • the proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance of the required particle size in the case of dispersions, by the use of surfactants, or by the use of a substance, such as lecithin (e.g., a coating).
  • Solutions of the active compounds as free acid or pharmacologically acceptable salts can be prepared in water suitably mixed with hydroxypropylcellulose and/or a pharmaceutically acceptable surfactant.
  • the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
  • isotonic agents for example, sugars, buffers or sodium chloride.
  • Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
  • Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients as required, followed by filtered sterilization.
  • dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
  • the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered, pyrogen-free solution thereof.
  • the compounds according to the invention may be presented in unit dose form in ampules, pre-filled syringes, small volume infusion containers, multi-dose containers with an added preservative, or indwelling pumps or dispensers, or in devices which allow for sustained release of the compounds.
  • the active GHB agent may be included within a therapeutic composition to comprise about 0.1 to about 100 grams GHB per unit dosage form, and multiple doses can also be administered.
  • one dosage could be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml of fluid or injected at the proposed site of infusion (see, for example, “Remington's Pharmaceutical Sciences” 15th Edition, pages 1035-1038 and 1570-1580).
  • Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject.
  • other pharmaceutically acceptable forms include, e.g., tablets or other solids; liposomal formulations; time release capsules; and any other form currently used, including creams or lotions, which then may be admixed with an aqueous medium for oral administration.
  • compositions suitable for oral administration may be presented as discrete unit dosage forms such as hard or soft gelatin capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or as granules; as a solution, a suspension or as an emulsion; or in a chewable base such as a synthetic resin or chicle for ingestion of the active ingredient from a chewing gum.
  • the active ingredient may also be presented as a bolus, syrup, electuary or paste.
  • Tablets and capsules for oral administration may contain conventional excipients such as binding agents, fillers, lubricants, disintegrants, or wetting agents.
  • the tablets may be coated according to methods well known in the art, i.e., with enteric coatings.
  • the tablets, troches, pills, capsules and the like may also contain the following: a binder, natural as gum tragacanth, acacia, cornstarch, or gelatin or synthetic as polyvinyl acetate; excipients, such as dicalcium phosphate; a disintegrating agent, such as corn starch, potato starch, alginic acid and the like; a lubricant, such as magnesium stearate; and a sweetening agent, such as sucrose, lactose, aspartame or saccharin may be added or a natural or synthetic flavoring agent.
  • a binder natural as gum tragacanth, acacia, cornstarch, or gelatin or synthetic as polyvinyl acetate
  • excipients such as dicalcium phosphate
  • a disintegrating agent such as corn starch, potato starch, alginic acid and the like
  • a lubricant such as magnesium stearate
  • a sweetening agent such as sucrose, lac
  • the dosage unit form When the dosage unit form is a capsule for admixing with a specific volume of an aqueous medium, it may contain, in addition to materials of the above type, a liquid carrier, such as vegetable oil or a polyethylene glycol. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules may be coated with gelatin, wax, shellac, sugar, natural or synthetic polymers, or both. A syrup or elixir may contain the active compounds, sucrose or fructose as a sweetening agent, a preservative, a dye and/or a flavoring. Of course, any material used in preparing any unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts employed.
  • compositions and preparations should contain at least 0.1% of the active compound.
  • the percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2 to about 75% of the weight of the unit, or preferably between 25-60%.
  • the amount of active compounds in such therapeutically useful compositions is such that a suitable dosage will be obtained.
  • the GHB-containing agent may be packaged separately from or in combination with the excipients, salts, flavorings or any other components described herein, to be admixed with an aqueous medium in the case of oral or injectable formulations, or they may be incorporated directly with the food (i.e., a beverage, candy bar or cake) of the diet.
  • the present compounds may be applied in pure form, i.e., when they are liquids. However, it will generally be desirable to administer them to the skin as compositions or formulations, in combination with a dermatologically acceptable carrier, which may be a solid or a liquid.
  • a dermatologically acceptable carrier which may be a solid or a liquid.
  • useful dermatological compositions which can be used to deliver the compounds of formula I, II, or III to the skin are known to the art; for example, see Jacquet et al. (U.S. Pat. No. 4,608,392), Geria (U.S. Pat. No. 4,992,478), Smith et al. (U.S. Pat. No. 4,559,157) and Wortzman (U.S. Pat. No. 4,820,508).
  • Useful solid carriers for dermatological compositions include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina and the like.
  • Useful liquid carriers include water, alcohols or glycols or water-alcohol/glycol blends, in which the present compounds can be dissolved or dispersed at effective levels, optionally with the aid of non-toxic surfactants.
  • Adjuvants such as fragrances and additional antimicrobial agents can be added to optimize the properties for a given use.
  • the resultant liquid compositions can be applied from absorbent pads, used to impregnate bandages and other dressings, or sprayed onto the affected area using pump-type or aerosol sprayers.
  • Ointments, pastes, gels, lotions, soaps and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
  • Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or coloring agents.
  • Thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses or modified mineral materials can be employed.
  • compound(s) of formula (I), formula (II), or formula (III) may be formulated as the active ingredient of a transdermal patch.
  • Suitable transdermal delivery systems are disclosed, for example, in A. Fisher et al. (U.S. Pat. No. 4,788,603), Chien et al. (U.S. Pat. No. 5,145,682) or R. Bawa et al. (U.S. Pat. Nos. 4,931,279, 4,668,506 and 4,713,224).
  • the active ingredient can also be delivered via iontophoresis, e.g., as disclosed in U.S. Pat. Nos. 4,140,122, 4,383,529, or 4,051,842.
  • Formulations suitable for topical administration in the mouth include unit dosage forms such as lozenges comprising active ingredient in a flavored base, usually sucrose and acadia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; mucoadherent gels, and mouthwashes comprising the active ingredient in a suitable liquid carrier.
  • the above-described formulations can be adapted to provide sustained release of the active ingredient employed, e.g., by combination with certain hydrophilic polymer matrices, e.g., comprising natural gels, synthetic polymer gels or mixtures thereof.
  • compositions suitable for rectal administration wherein the carrier is a solid are most preferably presented as unit dose suppositories.
  • Suitable carriers include cocoa butter and other materials commonly used in the art, and the suppositories may be conveniently formed by admixture of the active compound with the softened or melted carrier(s) followed by chilling and shaping in molds.
  • Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing, in addition to the active ingredient, such carriers as are known in the art to be appropriate.
  • the compounds according to the invention are conveniently delivered form an insufflator, nebulizer or a pressurized pack or other convenient means of delivering an aerosol spray.
  • Pressurized packs may comprise a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • the dosage unit may be determined by providing a valve to deliver a metered amount.
  • the compounds according to the invention may take the form of a dry powder composition, for example, a powder mix of the compound and a suitable powder base such as lactose or starch.
  • the powder composition may be presented in unit dosage form in, for example, capsules or cartridges or, e.g., gelatin or blister packs from which the powder may be administered with the aid of an inhalator or insufflator.
  • the compounds of the invention may be administered via a liquid spray, such as via a plastic bottle atomizer.
  • a liquid spray such as via a plastic bottle atomizer.
  • these are the Mistometer® (Wintrop) and the Medihaler® (Riker).
  • Nasal solutions are usually aqueous solutions designed to be administered to the nasal passages in drops or sprays. Nasal solutions are prepared so that they are similar in many respects to nasal secretions, so that normal ciliary action is maintained.
  • the aqueous nasal solutions usually are isotonic and lightly buffered to maintain a pH of 5.5 to 6.5, though other pH ranges disclosed herein the specific example, such as pH 3 to about pH 9, or pH 6 to about 7.5, are contemplated.
  • preservatives similar to those used in ophthalmic preparations, and appropriate drug stabilizers, if required, may be included in the formulation.
  • Various commercial nasal preparations are known and include, for example, antibiotics and antihistamines and are used for asthma prophylaxis.
  • GHB has typically been administered in clinical trials as an oral solution (Lee, 1977; Mamelak, 1977; Hoes, 1980; Scharf, 1985; Scrima, 1990; Gallimberti, 1992; Series, 1992; Lammers, 1993).
  • the dosages When used as an oral solution, the dosages have ranged from 20-45 milligrams per kilogram body weight, twice daily. (Mamelak, 1977.)
  • the amount of the compound of formula (I), (II), (III), (IV) or (V) required for use in treatment will vary not only with the particular compound selected but also with the route of administration, the severity of the condition being treated and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or clinician.
  • Useful dosages of the compounds of formula (I), (II), (III), (IV) or (V) can be determined by comparing their in vitro activity, and in vivo activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art; for example, see U.S. Pat. No. 4,938,949.
  • the concentration of the compound(s) of formula (I), (II), (III), (IV) or (V) in a liquid composition, such as a lotion will be from about 0.01-25 wt-%, preferably from about 0.5-10 wt-%.
  • concentration in a semi-solid or solid composition such as a gel or a powder will be about 0.01-15 wt-%, preferably about 0.5-2.5 wt-%.
  • a suitable dose will be in the range of from about 0.05 to 50 gm per day; or preferably from about 0.05 to about 500 mg per kilogram body weight of the recipient per day, preferably in the range of 0.1 to 200 mg/kg/day.
  • the compound is conveniently administered in unit dosage form; for example, containing 0.1-20 g, conveniently 1-7.5 g, or more conveniently, 2-5 g of active ingredient per unit dosage form.
  • the total daily dose i.e., of about 0.05-50 g, may be administered for about 1-4 months, or longer, as needed.
  • the active ingredient should be administered to achieve peak plasma concentrations of the active compound of from about 0.5 to about 75 ⁇ M, preferably, about 1 to 50 ⁇ M, most preferably, about 2 to about 30 ⁇ M. This may be achieved, for example, by the intravenous injection of a 0.05 to 5% solution of the active ingredient, optionally in saline, or orally administered as a bolus containing about 1-100 mg of the active ingredient. Desirable blood levels may be maintained by continuous infusion to provide about 0.01-5.0 mg/kg/hr or by intermittent infusions containing about 0.4-15 mg/kg of the active ingredient(s).
  • the desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day.
  • the sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations; such as multiple inhalations from an insufflator or by application of a plurality of drops into the eye.
  • reaction mixture was washed with 300 ml H 2 O, the organic layer was isolated and washed with 100 ml in HCl aq, 100 ml NaCl aq and dried over MgSO 4 (anhydrous). The solvents were removed in vacuo to yield the product (VII) as a translucent low viscosity oil.

Abstract

The present invention provides compositions comprising at least one GHB moiety bonded to at least one physiologically compatible carrier molecule. The compositions can enhance the uptake of the drug, deliver effective therapeutic doses in a time-delayed fashion, or can target specific organs.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a divisional of U.S. application Ser. No. 11/183,482, filed on Jul. 18, 2005, which is a divisional of U.S. application Ser. No. 10/381,224, filed on Mar. 21, 2003, which is a U.S. National Stage filing under 35 U.S.C. 371 from International Application No. PCT/US01/29569, filed Sep. 21, 2001 and published in English as WO 02/24715 A2 on Mar. 28, 2002, which claims priority from U.S. Provisional Application Ser. No. 60/234,720 filed on Sep. 22, 2000, the disclosures of which applications and publication are incorporated by reference herein in their entirety.
    • BACKGROUND OF THE INVENTION
  • Gamma-hydroxybutyric acid or “gamma-hydroxybutyrate” (GHB) is an endogenous compound with hypnotic properties that is found in many human body tissues. GHB is present, for example, in the mammalian brain, the human nervous system and other tissues. The extraordinary range of the pharmacological effects of GHB or its salts has attracted scientific attention for more than three decades. For example, GHB has been found to have tissue-protective effects in animals and man in many different organs including brain, liver, lung, heart, kidney, gut and pancreatic B cells. In brain the highest GHB concentration is found in the hypothalamus and basal ganglia and GHB is postulated to function as a neurotransmitter (Snead and Morley, 1981). The neuropharmacologic effects of GHB include increases in brain dopamine, depression of glucose utilization but not oxygen consumption in the brain, and hypothermia. GHB is converted to succinate and then metabolized via the Krebs cycle. Clinical trials have shown that GHB increases delta sleep and improves the continuity of sleep (Ladinsky et al., 1983; Stock et al., 1973; Laborit, 1973; Lapierre et al., 1990; Yamada et al., 1967; Grove-White and Kelman, 1971; Scharf, 1985).
  • In healthy human volunteers, low doses (about 30 mg/kg) of GHB monosodium salt (sodium oxybate) promote a normal sequence of NREM and REM sleep lasting about 2-3 hours. These low doses also can induce REM and slow wave sleep and, in contrast to the hypnotics in common use, without the development of tolerance to these sleep-inducing effects in time. In addition, GHB increases total sleep time and REM sleep, and it decreases REM latency (Mamelak et al., 1973; Yamada et al., 1967; Bedard et al., 1989), reduces sleep apnea (Series et al., 1992; Scrima et al., 1987), and improves general anesthesia (Hasenbos and Gielen, 1985).
  • Studies by R. Broughton and M. Mamelak, Can. J. Neur. Sci., 7, 23 (1980), L. Scrima et al., Sleep, 13, 479 (1990), and M. B. Scharf et al., Am. Fam. Phys., 143 (July 1988) have evaluated the effects of GHB in the treatment of narcolepsy. The results of these studies confirm that GHB treatment substantially reduces the signs and symptoms of narcolepsy (e.g., daytime sleepiness, cataplexy, sleep paralysis and hypnagogic hallucinations).
  • GHB has several clinical applications other than the treatment of sleep disorders. GHB has been reported to reduce alcohol craving, the number of daily drinks consumed, and the symptoms of alcohol withdrawal in patients (Gallimberti et al., 1989; Gallimberti et al., 1992; Gessa et al., 1992). GHB has been used to decrease the symptoms of opiate withdrawal, including both heroin and methadone withdrawal (Gallimberti et al., 1994; Gallimberti et al., 1993). It has analgesic effects that make it suitable as a pain reliever (U.S. Pat. No. 4,393,236). Intravenous administration of GHB has been reported to reduce intracranial pressure in patients (Strong, A. 1984). Also administration of GHB was reported to increase growth hormone levels in patients (Gerra et al., 1994; Oyama et al., 1970). GHB is also an effective therapeutic agent for the treatment of chronic fatigue syndrome and fibromyalgia (Scharf, U.S. Pat. No. 5,990,162).
  • Unfortunately, the efficacy of GHB is limited by the high doses required to produce a therapeutic effect and by its short duration of action. Thus, a need exists for GHB compositions that can enhance the uptake of the drug, deliver effective therapeutic doses in a time-delayed fashion, and target specific organs.
    • SUMMARY OF THE INVENTION
  • The present invention provides a compound of formula (I):
    Figure US20100022643A2-20100128-C00001
    wherein Y is H or a hydroxyl-protecting group, X is the residue of a carbohydrate and n has a value of 1 to the number of available hydroxyl groups in said carbohydrate, or a pharmaceutically acceptable salt thereof.
  • Preferably, X is a saccharide, and Y is H, a (C4-C6)acetal, (C1-C5)acyl or (C1-C5)alkyl.
  • Preferred carbohydrates are water-soluble or water-dispersible. In yet another preferred embodiment of the invention, X is the residue of a monosaccharide, the residue of a disaccharide or the residue of a polysaccharide.
  • In such compounds, the monosaccharide, disaccharide or polysaccharide can contain at least one CHOH—CHOH residue that is protected as an acetal or ketal.
  • Examples of compounds of formula (I) include 1,2,3,4,6-pentakis(4-hydroxy-butyroyl)hexanose; 6-(4-hydroxy-butyroyl)hexanose and 1,2,3,4,6-pentakis(4-acetoxybutyroyl)hexanose.
  • In a further preferred embodiment of the compound of formula (I), X is the residue of a chemically-modified cellulose. Useful chemically-modified cellulose compositions include water-soluble or water-dispersible celluloses such as hydroxypropyl-methylcellulose, hydroxypropylcellulose or hydroxyethylcellulose.
  • Further provided by the present invention is a compound of formula (II):
    (R1O(CH2)3CO2)m(ROC(O)(CH2)3C(O))q—(X)—(Y)n-(Z)n-(CO2(CH2)3CO2R)p(O2C(CH2)3OR′)k  (II)
    wherein R′ is H or a hydroxyl protecting group, R′ is H, (C1-C4)alkyl or benzyl, X and Z are each residues of a hydroxy group-containing amino acid or a bis(carboxy)amino acid, Y is a moiety covalently linking X and Z, n is 0-1, m and k are 0 to the number of available OH groups is X and Z, q and p are 0 to the number of available CO2 groups on X and Z, with the proviso that m and q are not both zero and p and k are not both zero, or a pharmaceutically acceptable salt thereof.
  • An embodiment of the compound of formula II is a compound of formula (III):
    Figure US20100022643A2-20100128-C00002
    wherein R1 is H or a hydroxyl-protecting group, R is H, (C1-C4) alkyl or benzyl, X is a residue of a hydroxy group-containing amino acids, Z is a residue of a hydroxy group-containing amino acid or a bis(carboxy)amino acid, Y is a moiety covalently linking X and Z, n is 0-1, m is 1 to the number of hydroxy groups on amino acid X, p is 1 to the number of CO2H groups on the amino acid X or Z, or a pharmaceutically acceptable salt thereof.
  • Preferably, m, p, q and k are individually 0-5, more preferably 0-3, and most preferably 0-2.
  • In one preferred embodiment of the compound of formula (III), m=p=1, n is O and X is glutamic acid, tyrosine, aspartic acid, threonine, or a serine. In another preferred embodiment of the compound of formula (III), m=p=1, n is 1, and Y is C(O)CH2CH2C(O) or C(O)CH═CH(CO).
  • The present invention also provides a compound of formula (IV):
    Figure US20100022643A2-20100128-C00003
    wherein L and L′ are individually H, (C1-C6)alkyl or a hydroxyl protecting group or an organic moiety comprising at least one fatty alcohol, ester or analog thereof. At least one of L and L′ is said moiety (the FA moiety). Preferably, the FA moiety is (A)(Y)(Z)n, and wherein A is (C2-C6)alkyl, Y is H, OH, N(R1)(R2)(R3) or [—O(PO3 −)-L-N(R1)(R2)(R3)] wherein R1, R2 and R3 are each (C1-C4)alkyl or R1 and R2 together with N are a (C5-C7)heterocyclic ring, optionally substituted with 1 or 2 N(R3), S, non-peroxide O or a combination thereof; n is 1-2 and Z is YR, wherein Y is O, S, NH, N(CH3), NHC(O) or OC(O) and R is (C8-C22)alkyl, optionally substituted with 1-2 double bonds.
  • Preferably, one of L or L′ is (A)(Y)(Z)n and the other is H; n=1, YZ is (C10-C20)alkylC(O), R1, R2 and R3 are methyl and/or A is propyl or ethyl. Preferably, when L′ is a 2-substituted lecithin moiety, i.e., the C2OC(O)R2 moiety of lecithin is replaced by C2C(O)(CH2)3OL and Y is hexadecanoyl; L is not H. Preferably n=1 and (A)(Y)(Z)n is —CH[CH2Y][CH2Z], e.g., is derived by replacement of the 2′-acyloxyl moiety of lecithin with L-O(CH2)3C(O)—. When one of L or L′ is 1,3-dihexdecanoylprop-2-yl, the other is not H.
  • Generally, L and L′ are derived from organic polyols, such as glycerol, ethylene glycol, propylene glycol, 2,2′-hydroxyethyl ether and the like. The organic moieties L and L′ can also be simple fatty acid esters of C4—OH or fatty alcohol esters of CO2H.
  • The present invention also provides compounds of formula (V):
    Figure US20100022643A2-20100128-C00004
    wherein L is defined above, n is 2-6, preferably 2-5, most preferably 2-3, and L″ is (C2-C12) alkyl, preferably (C3-C10)alkyl, most preferably (C3-C6)alkyl, wherein the alkyl chain is optionally interrupted by about 1-3-O-moieties, i.e., is the residue of an alkylene polyol, preferably a 1,ω-alkylene diol such as 1,3-propane diol, or a polyoxyalkylene glycol. Examples of compounds of formula (V) include 1,2,3-tris(4-hydroxy-butyroyoxyl)propane and 1,3-bis(4-acetoxybutyroyoxyl)propane.
  • The present invention also provides a pharmaceutical composition comprising an effective amount of the compound of formula (I), (II), (III) or (IV), or mixtures thereof in combination with a pharmaceutically acceptable carrier. The pharmaceutical composition of the present invention may be adapted for parenteral, oral, topical or local administration.
  • The present invention also provides a therapeutic method comprising administering to a mammal afflicted with a pathology or condition ameliorated by GHB, an amount of a compound of formula I, II, III, IV and/or V effective to treat said pathology or condition.
  • As used herein, the term “effective amount” means that the composition can deliver an amount of GHB to a target cell, tissue or organ effective to accomplish a therapeutic objective, i.e., to alter cellular metabolism or energetics or to ameliorate at least one symptom of one of the pathologies discussed herein.
    • BRIEF DESCRIPTION OF THE FIGURES
  • The following drawings from part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.
  • FIG. 1A shows a compound comprising the GHB pentaester of a fully charged hexopyranose.
  • FIG. 1B shows GHB triesters of partially charged hexopyranoses.
  • FIG. 2 shows a GHB-sucrose ester.
  • FIG. 3 shows a GHB linked to representative amino acids.
  • FIG. 4 shows a GHB linked to amino acid conjugates.
    • DETAILED DESCRIPTION OF THE INVENTION A. Definitions
  • The term “amino acid” comprises the residues of the natural amino acids (e.g. Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Hyl, Hyp, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, and Val) in D or L form, as well as unnatural amino acids (e.g. phosphoserine, phosphothreonine, phosphotyrosine, hydroxyproline, gamma-carboxyglutamate; hippuric acid, octahydroindole-2-carboxylic acid, statine, 1,2,3,4,-tetrahydroisoquinoline-3-carboxylic acid, penicillamine, ornithine, citruline, α-methyl-alanine, para-benzoylphenylalanine, phenylglycine, propargylglycine, sarcosine, and tert-butylglycine). The term also comprises natural and unnatural amino acids bearing a conventional amino protecting group (e.g. acetyl or benzyloxycarbonyl), as well as natural and unnatural amino acids protected at the carboxy terminus (e.g. as a (C1-C6)alkyl, phenyl or benzyl ester or amide; or as an α-methylbenzyl amide). Other suitable amino and carboxy protecting groups are known to those skilled in the art (See for example, T. W. Greene, Protecting Groups In Organic Synthesis; Wiley: New York, 1981, and references cited therein). An amino acid can be linked to the remainder of a compound of formula I through the carboxy terminus, the amino terminus, or through any other convenient point of attachment, such as, for example, through the sulfur of cysteine.
  • The term “hydroxy amino acid” includes naturally occurring, synthetic and semi-synthetic amino acids, such as serine, threonine, tyrosine and hydroxyproline. Preferably the amino acids are α-amino acids, most preferably with ω-hydroxyl groups.
  • The term “carbohydrate” as used herein is defined to include polyhydroxy aldehydes, or polyhydroxy ketones or substances that yield such compounds on hydrolysis. The term “carbohydrate” includes monosaccharides, oligosaccharides, disaccharides, trisaccharides, tetrasaccharides, pentasaccharides, hexasaccharides, polysaccharides, homopolysaccharides, and heteropolysaccharides. The term includes any of the aldoses, as well as glucose, dextrose, mannose, galactose arabinose, xylose, ribose, fructose, sucrose, altrose, allose, idose, gulose, talose, lyxose, threose, erythrose, apiose, and any of the same in acid form. The term also includes deoxy sugars and deoxy-aldoses, including rhamnose and fucose. The term further includes glyceraldehyde, cellulose, starch, glycogen, and amylose. The term also includes carbohydrate derivatives, such as acetals, ketals, acyl esters and the like. Chemically modified polysaccharides such as sucralfate and modified starches are also within the scope of the term. Additional suitable carbohydrates of the present invention may be found in Noller, C., Chemistry of Organic Compounds, 2nd ed. (W. B. Saunders Co., 1957).
  • The term “saccharide” includes monosaccharides, disaccharides, trisaccharides and polysaccharides. The term includes glucose, sucrose, fructose and ribose, as well as deoxy sugars such as deoxyribose and the like. Saccharide derivatives can conveniently be prepared as described in International Patent Applications Publication Numbers WO 96/34005 and 97/03995.
  • The term “oligopeptide” describes a sequence of 2 to 25 amino acids (e.g. as defined hereinabove) or peptidyl residues. The sequence may be linear, branched or cyclic. For example, a cyclic peptide can be prepared or may result from the formation of disulfide bridges between two cysteine residues in a sequence. An oligopeptide can be linked to the remainder of a compound of formula I through the carboxy terminus, the amino terminus, or through any other convenient point of attachment, such as, for example, through the sulfur of a cysteine. Preferably a peptide comprises 3 to 25, or 5 to 21 amino acids. Peptide derivatives can be prepared as disclosed in U.S. Pat. Nos. 4,612,302; 4,853,371; and 4,684,620.
  • The term “linking moiety” or “linker” as used herein refers to an at least divalent organic molecule that can join two amino acids or oligopeptidyl residues by reaction with functional groups therein. Such moieties include alkane and alkene dicarboxylic acids and diamines.
  • The term “alkyl” includes branched, straight-chain and cyclic alkyl groups, including (cycloalkyl)alkyl.
  • A fatty alcohol is a (C8-C22)alkanol, preferably a (C10-C20)alkanol, optionally comprising 1-3 double bonds; a fatty acid is a (C8-C22)alkanoic acid (i.e., (C1-C11)C(O)OH), optionally comprising 1-3 double bonds.
  • The term “hydroxyl protecting group” includes removable hydroxy moiety protecting groups known to the art, such as acid- or base-labile groups such as acetals (THP, (1-ethoxy)ethyl), tris(alkyl)silyl groups (Me3, Si, (t-Bu(Me2)Si)), (C2-C7)acyl groups (acetyl), as well as groups that can be removed by hydrogenolysis, such as benzyl. See, also, part (C)(a), hereinbelow, which references additional OH protecting groups.
    • B. Applications
  • GHB has been shown to be effective in treating narcolepsy and sleep disorders (Lee, 1977; Mamelak, 1977; Hoes, 1980; Scharf, 1985; Scrima, 1990; Gallimberti, 1992; Series, 1992; Lammers, 1993), reducing alcohol craving and alcohol withdrawal symptoms (Gallimberti et al., 1989; Gallimberti et al., 1992; Gessa et al., 1992), reducing opiate withdrawal symptoms (Gallimberti et al., 1994; Gallimberti et al., 1993), reducing pain (U.S. Pat. No. 4,393,236), reducing intracranial pressure in patients (Strong, A., 1984), and increasing growth hormone levels in patients (Gerra et al., 1994; Oyama et al., 1970). The compounds and compositions of the present invention can also be used in the treatment of any of these disorders or conditions in patients.
  • GHB has been used with other analgesics, neuroleptics, or with a subliminal barbiturate dose for use as an anesthesia. GHB has been used in closed cranio-cerebral trauma and as soporifics (U.S. Pat. No. 5,380,937). Therefore, the compounds of the present invention can also be used in combination with analgesics, neuroleptics or barbiturates for use as an anesthesia. The inventors contemplate the use of the GHB compositions of the present invention as a narcotic, hypnotic, or as a soporific.
  • The present invention provides compounds and pharmaceutical compositions that can be used in the treatments of hypnosis; narcolepsy (particularly cataplexy); drug abuse; anxiety; cerebrovascular diseases; central nervous system disorders, neurological disorders, including Parkinson's Disease and Alzheimer Disease; Multiple Sclerosis; autism; depression; inflammatory disorders, including those of the bowel, such as irritable bowel disorder, regional illitis, and ulcerative collitis; autoimmune inflammatory disorders; certain endocrine disturbances and diabetes. The present compounds can also be administered for the purpose of tissue protection, including protection following hypoxia/anoxia such as in stroke, organ transplantation, organ preservation, myocardial infarction or ischemia/reperfusion injury; protection following radiation, progeria, or an increased level of intracranial pressure, e.g., due to head trauma. The present compounds can be used to treat other pathologies believed to be caused or exacerbated by lipid peroxidation and/or free radicals, such as pathologies associated with oxidative stress, including normal aging.
    • C. Availability and Preparation of Compounds of the Present Invention
  • GHB is available from the Aldrich Chemical Co., Milwaukee, Wis., and can be employed to prepare the compounds within the scope of formula (I) or (II). The GHB compositions of the present invention can be prepared by and administered by any of the means described herein, particularly those described in the section and the examples, or by any means as would be known to those of skill in the art.
  • A compound of the present invention can be employed as the free acid or alcohol, or as a pharmaceutically acceptable salt or ester thereof. Such salts can be formed from acids or amino groups described herein, by methods available to one or ordinary skill in the art. In cases where compounds are sufficiently basic or acidic to form stable salts with nontoxic organic acids or metal salts, administration of the compounds as salts may be appropriate. Examples of pharmaceutically acceptable salts are organic acid addition salts formed with acids which can form a physiological acceptable anion, for example, tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate, α-ketoglutarate, and α-glycerophosphate. Suitable inorganic salts may also be formed, including hydrochloride, sulfate, nitrate, bicarbonate, and carbonate salts. Pharmaceutically acceptable salts may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically acceptable anion. Alkali metal (for example, sodium, potassium or lithium) or alkaline earth metal (for example calcium) salts of carboxylic acids can also be made. The cations can also be readily exchanged with other metal or organic cations, such as Ca+, K+, Li+, or (R)4N+ wherein each R is H, phenyl, (C1-C6)alkyl or hydroxy(C1-C6)alkyl, i.e., ammonium or hydroxyethyl amine salts.
  • Hydroxy protecting groups such as esters, ethers, acetals and ketals may be utilized in the present compounds. Useful hydroxy protecting groups are descried in Greene, T. W.; Wutz, P. G. M., “Protecting Groups in Organic Synthesis”, 2nd ed., John Wiley & Sons, Inc (1991).
  • a) Preparation of Carbohydrate-GHB Compounds
  • GHB can be esterified with (C1-C4)alkanols or the benzyl ester prepared. For ester preparation methods, see S. Ege, Organic Chemistry, p. 454-455, 459, 466-467 (D.C. Heath and Co., 1984). See also, Pouillart et al., Eur. J. Pharm. Sci., 7, 93-106 (1998). Then the OH group can be protected by formation of an acetal or by alkanoylation or benzoylation with an alkanoyl or benzoyl chloride or with anhydrides. Other useful acid- and base-labile hydroxy-protecting groups are described in Greene, T. W.; Wutz, P. G. M. “Protecting Groups In Organic Synthesis” second edition, 1991, New York, John Wiley & Sons, Inc.
  • The ester can be removed and the acid can be activated if necessary, i.e., by formation of an acid chloride or anhydride. For preparation methods for 4-hydroxy-butanoic acid and its derivatives, see, Marvel et al., J. Am. Chem. Soc., 51, 260 (1929); Japanese patent 63174947, German Pat. Nos. 237310, 237308 and 237309.
  • The activated carboxyl group of GHB can be reacted with the target hydroxyl groups in various sugars via ester bonds, as described, for example, in P. Pouillart et al., Eur. J. Pharm. Sci., 7, 93 (1998), P. R. Pouillart, Life Sciences, 63, 1739 (1998); P. Pouillart et al., J. Pharm. Sci., 81, 241 (1992), and references cited therein. Most types of sugars, including triose (or glycerol) tetroses, pentoses and hexoses can be used to make the compounds of the present invention. In the latter two cases, the open chain and ring (pyranoses and furanoses) forms may be used as scaffolds. An example of hexopyranose is depicted in FIG. 1 a, where a maximum of 5 GHB molecules can be anchored to each sugar monomer.
  • The therapeutic potential of these compounds is dependant on the stability of the compounds in various environments. It is contemplated that fully charged GHB compounds can be synthesized from sucrose (containing a furanose and a pyranose ring), glucose and one from any open chain hexose. These compounds may be synthesized by a single step from free GHB or from its lactone.
  • In a fully charged molecule, i.e, (GHB)5-Sugar, the hydrocarbon chains may provide adequate protection from enzymes present in the digestive tract. These compositions may be susceptible to acid catalyzed hydrolysis, which depends on the steric environments around each ester bond. For example, the 6-OH ester bond will be readily hydrolyzed. These molecules may be viewed as miniature micelles and can be transported into the circulatory system via the fat absorption mechanism.
  • Linking GHB to partially charged sugars may provide for better uptake and delivery of the drug. As seen in FIG. 1 b, the depicted compound has only 3-GHBs attached to the sugar. The choice of hydroxyl groups for esterification can be based on the rates of hydrolysis of the corresponding esters so that desired levels of free GHB can be maintained within the cells of the target organ.
  • Free hydroxyl groups can be used to anchor various groups. Steric shielding of GHB-ester linkages enhances the stability of the compounds in acidic medium. For example, one or more pairs of adjacent OH group groups on the sugar ring can be protected as acetals or as ketals, as taught by Pouillart et al., cited above, using acetals. The ketone can be varied in bulk, in order to shield the ester linkages to a greater or lesser extent. The attachment of lipophilic groups, such as steroids or fatty acids, to GHB via e.g., ketal or acetal linkages, can enhance the transfer across the blood-brain barrier. The use of a ketosteriod or benzaldehyde to form a ketal or acetal is shown in FIG. 1(b). A lipophilic composition may also be useful for delivery of GHB via salves or dermal patches. Free hydroxyl groups of the sugar may also be used to attach a second complementary therapeutic agent to the GHB composition.
  • b) Preparation of GHB Amino Acid Compounds
  • Amino acids (AA), serine, threonine, tyrosine, aspartic acid and glutamic acid contain side chains containing OH groups and/or second CO2H groups that can be coupled to GHB by ester linkages, following N-protection (See FIG. 3). Each of these compounds could be linked to two GHB molecules. Alternatively, the carboxylic acid of GHB can be reacted with an acid-protected amino acid to form the amide from the amine of the amino acid. Because the ester linkages of these compounds have different steric environments, the hydrolysis rates of these compounds in vivo will vary. A significantly slow rate of hydrolysis will be seen with serine and threonine, due to the ester linkages associated with their side chains. For tyrosine, the ester linkage associated with the phenoxy side chain can be very rapidly hydrolyzed. Single amino acid compounds, i.e., AA-(GHB)2 can only deliver 2 GHB molecules, and due to the lack of steric shielding, these compounds may have limited stability in the stomach pH. However, tailored small peptides having 3 to 5 amino acids can significantly improve the quantity of GHB delivered and have enhanced stability.
  • It is contemplated that the compounds of the present invention may comprise two or more amino acids. Such compounds can be constructed by using covalent linking moieties such as succinic acid to couple the amino acids tyrosine and threonine, or using maleic acid to couple aspartic and glutamic acids. Each of these conjugates comprises 4 GHB per molecule, where each ester linkage is in a significantly different steric shielding. (See FIG. 4). As backbones of the compounds, the succinic and maleic acid linkers have significantly different degrees of flexibility. Succinic acid has full rotational freedom, whereas using maleic acid, GHB molecules will be held in a cis orientation. Each compound, having two amide and four ester linkages, can give rise to distinct structural organizations with different stability and cellular uptake.
  • c) Preparation of Compounds of Formulas (IV) and (V)
  • Analogs of naturally occurring phospholipids and lipids are known to the art.
  • The compounds of formula III can be prepared as disclosed in PCT WO 92/03462; U.S. Pat. No. 5,223,263; PCT/US91/04289; or PCT/US94/05855. Lecithin or a sphingolipid can be partially hydrolyzed to yield one or more free OH groups and GHB attached as discussed above.
  • Compounds of formula (V) can be prepared by the reaction of polyols (L″(OH)n) with 4-halobutyroylchloride, which is then hydrolyzed and the 4-hydroxyl group protected, or the 4-halo group is displaced by L″O− or an equivalent thereof.
    • D. Administration
  • The invention provides a pharmaceutical formulation comprising a compound of formula (I), (II), or (III), together with one or more pharmaceutically acceptable carriers therefor and, optionally, other therapeutic and/or prophylactic ingredients. The cations and carrier(s) must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof, i.e., they do not produce an adverse, allergic, or other untoward reaction when administered to an animal, or a human, at appropriate levels.
  • Pharmaceutical formulations include those suitable for oral or parenteral (including intramuscular, subcutaneous and intravenous) administration. Forms suitable for parenteral administration also include forms suitable for administration by inhalation or insufflation or for nasal, or topical (including buccal, rectal, vaginal, transdermal or sublingual) administration. The formulations may, where appropriate, be conveniently presented in discrete unit dosage forms, by bringing the active compound into association with liquid carriers, solid matrices, semi-solid carriers, finely divided solid carriers or combinations thereof, and then, if necessary, shaping the product into the desired delivery system.
  • a) Parenteral Administration and Dosage Forms
  • The active compounds of the invention may be formulated for parenteral administration, e.g., formulated for injection via intravenous, intraarterial, intramuscular, subcutaneous, intralesional, intraperitoneal or other parenteral routes. The preparation of an aqueous composition that contains a GHB agent as an active component or ingredient will be known to those of skill in the art in light of the present disclosure.
  • The pharmaceutical dosage forms suitable for injection or infusion can include sterile aqueous solutions or dispersions or sterile powders comprising the active ingredient which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions. The compounds of the invention may be lyophilized for more ready formulation into a desired vehicle where appropriate. For injection or infusion, the active agent can optionally be encapsulated in liposomes. In all cases, the ultimate dosage form should be sterile, fluid and stable under the conditions of manufacture and storage.
  • The liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, glycerol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance of the required particle size in the case of dispersions, by the use of surfactants, or by the use of a substance, such as lecithin (e.g., a coating). Solutions of the active compounds as free acid or pharmacologically acceptable salts can be prepared in water suitably mixed with hydroxypropylcellulose and/or a pharmaceutically acceptable surfactant. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, buffers or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
  • Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered, pyrogen-free solution thereof. The preparation of more, or highly, concentrated solutions for direct injection is contemplated, where the use of DMSO as solvent (although DMSO may not now be a permitted human drug) is envisioned to result in extremely rapid penetration, delivering high concentrations of the active agents to a small area.
  • The compounds according to the invention may be presented in unit dose form in ampules, pre-filled syringes, small volume infusion containers, multi-dose containers with an added preservative, or indwelling pumps or dispensers, or in devices which allow for sustained release of the compounds.
  • The active GHB agent may be included within a therapeutic composition to comprise about 0.1 to about 100 grams GHB per unit dosage form, and multiple doses can also be administered. As an example, one dosage could be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml of fluid or injected at the proposed site of infusion (see, for example, “Remington's Pharmaceutical Sciences” 15th Edition, pages 1035-1038 and 1570-1580). Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject.
  • b) Oral and Topical Administration and Dosage Forms
  • In addition to the compounds formulated for parenteral administration, other pharmaceutically acceptable forms include, e.g., tablets or other solids; liposomal formulations; time release capsules; and any other form currently used, including creams or lotions, which then may be admixed with an aqueous medium for oral administration.
  • Pharmaceutical formulations suitable for oral administration may be presented as discrete unit dosage forms such as hard or soft gelatin capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or as granules; as a solution, a suspension or as an emulsion; or in a chewable base such as a synthetic resin or chicle for ingestion of the active ingredient from a chewing gum. The active ingredient may also be presented as a bolus, syrup, electuary or paste. Tablets and capsules for oral administration may contain conventional excipients such as binding agents, fillers, lubricants, disintegrants, or wetting agents. The tablets may be coated according to methods well known in the art, i.e., with enteric coatings.
  • The tablets, troches, pills, capsules and the like may also contain the following: a binder, natural as gum tragacanth, acacia, cornstarch, or gelatin or synthetic as polyvinyl acetate; excipients, such as dicalcium phosphate; a disintegrating agent, such as corn starch, potato starch, alginic acid and the like; a lubricant, such as magnesium stearate; and a sweetening agent, such as sucrose, lactose, aspartame or saccharin may be added or a natural or synthetic flavoring agent.
  • When the dosage unit form is a capsule for admixing with a specific volume of an aqueous medium, it may contain, in addition to materials of the above type, a liquid carrier, such as vegetable oil or a polyethylene glycol. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules may be coated with gelatin, wax, shellac, sugar, natural or synthetic polymers, or both. A syrup or elixir may contain the active compounds, sucrose or fructose as a sweetening agent, a preservative, a dye and/or a flavoring. Of course, any material used in preparing any unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts employed.
  • Such compositions and preparations should contain at least 0.1% of the active compound. The percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2 to about 75% of the weight of the unit, or preferably between 25-60%. The amount of active compounds in such therapeutically useful compositions is such that a suitable dosage will be obtained.
  • The GHB-containing agent may be packaged separately from or in combination with the excipients, salts, flavorings or any other components described herein, to be admixed with an aqueous medium in the case of oral or injectable formulations, or they may be incorporated directly with the food (i.e., a beverage, candy bar or cake) of the diet.
  • For topical administration, the present compounds may be applied in pure form, i.e., when they are liquids. However, it will generally be desirable to administer them to the skin as compositions or formulations, in combination with a dermatologically acceptable carrier, which may be a solid or a liquid. Examples of useful dermatological compositions which can be used to deliver the compounds of formula I, II, or III to the skin are known to the art; for example, see Jacquet et al. (U.S. Pat. No. 4,608,392), Geria (U.S. Pat. No. 4,992,478), Smith et al. (U.S. Pat. No. 4,559,157) and Wortzman (U.S. Pat. No. 4,820,508).
  • Useful solid carriers for dermatological compositions include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina and the like. Useful liquid carriers include water, alcohols or glycols or water-alcohol/glycol blends, in which the present compounds can be dissolved or dispersed at effective levels, optionally with the aid of non-toxic surfactants. Adjuvants such as fragrances and additional antimicrobial agents can be added to optimize the properties for a given use. The resultant liquid compositions can be applied from absorbent pads, used to impregnate bandages and other dressings, or sprayed onto the affected area using pump-type or aerosol sprayers.
  • Ointments, pastes, gels, lotions, soaps and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or coloring agents. Thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses or modified mineral materials can be employed.
  • For systemic administration or as topical administration to the epidermis, compound(s) of formula (I), formula (II), or formula (III) may be formulated as the active ingredient of a transdermal patch. Suitable transdermal delivery systems are disclosed, for example, in A. Fisher et al. (U.S. Pat. No. 4,788,603), Chien et al. (U.S. Pat. No. 5,145,682) or R. Bawa et al. (U.S. Pat. Nos. 4,931,279, 4,668,506 and 4,713,224). The active ingredient can also be delivered via iontophoresis, e.g., as disclosed in U.S. Pat. Nos. 4,140,122, 4,383,529, or 4,051,842.
  • Formulations suitable for topical administration in the mouth include unit dosage forms such as lozenges comprising active ingredient in a flavored base, usually sucrose and acadia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; mucoadherent gels, and mouthwashes comprising the active ingredient in a suitable liquid carrier.
  • When desired, the above-described formulations can be adapted to provide sustained release of the active ingredient employed, e.g., by combination with certain hydrophilic polymer matrices, e.g., comprising natural gels, synthetic polymer gels or mixtures thereof.
  • Pharmaceutical formulations suitable for rectal administration wherein the carrier is a solid are most preferably presented as unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art, and the suppositories may be conveniently formed by admixture of the active compound with the softened or melted carrier(s) followed by chilling and shaping in molds.
  • Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing, in addition to the active ingredient, such carriers as are known in the art to be appropriate.
  • For administration by inhalation, the compounds according to the invention are conveniently delivered form an insufflator, nebulizer or a pressurized pack or other convenient means of delivering an aerosol spray. Pressurized packs may comprise a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount.
  • Alternatively, for administration by inhalation or insufflation, the compounds according to the invention may take the form of a dry powder composition, for example, a powder mix of the compound and a suitable powder base such as lactose or starch. The powder composition may be presented in unit dosage form in, for example, capsules or cartridges or, e.g., gelatin or blister packs from which the powder may be administered with the aid of an inhalator or insufflator.
  • For intra-nasal administration, the compounds of the invention may be administered via a liquid spray, such as via a plastic bottle atomizer. Typical of these are the Mistometer® (Wintrop) and the Medihaler® (Riker). Nasal solutions are usually aqueous solutions designed to be administered to the nasal passages in drops or sprays. Nasal solutions are prepared so that they are similar in many respects to nasal secretions, so that normal ciliary action is maintained. Thus, the aqueous nasal solutions usually are isotonic and lightly buffered to maintain a pH of 5.5 to 6.5, though other pH ranges disclosed herein the specific example, such as pH 3 to about pH 9, or pH 6 to about 7.5, are contemplated. In addition, preservatives, similar to those used in ophthalmic preparations, and appropriate drug stabilizers, if required, may be included in the formulation. Various commercial nasal preparations are known and include, for example, antibiotics and antihistamines and are used for asthma prophylaxis.
  • c) Dosages
  • A good safety profile for GHB consumption, when used long term for treatment of narcolepsy, has been reported. Patients have been safely treated for many years with GHB without development of tolerance (Scharf, 1985). Clinical laboratory tests carried out periodically on many patients have not indicated organ or other toxicities (Lammers, 1993; Scrima, 1990; Scharf, 1985; Mamelak, 1977; Mamelak; 1979; Gallimberti, 1989; Gallimberti, 1992; Gessa, 1992).
  • In the healthy volunteers study, the pharmacokinetics of three rising GHB doses (12.5, 25, and 50 mg/kg) were investigated. These findings indicate that both the oral absorption and elimination processes of GHB were capacity-limited though the degree of dose dependency was moderate (Palatini et al., 1993).
  • GHB has typically been administered in clinical trials as an oral solution (Lee, 1977; Mamelak, 1977; Hoes, 1980; Scharf, 1985; Scrima, 1990; Gallimberti, 1992; Series, 1992; Lammers, 1993). When used as an oral solution, the dosages have ranged from 20-45 milligrams per kilogram body weight, twice daily. (Mamelak, 1977.)
  • It will be appreciated that the amount of the compound of formula (I), (II), (III), (IV) or (V) required for use in treatment will vary not only with the particular compound selected but also with the route of administration, the severity of the condition being treated and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or clinician.
  • Useful dosages of the compounds of formula (I), (II), (III), (IV) or (V) can be determined by comparing their in vitro activity, and in vivo activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art; for example, see U.S. Pat. No. 4,938,949.
  • Generally, the concentration of the compound(s) of formula (I), (II), (III), (IV) or (V) in a liquid composition, such as a lotion, will be from about 0.01-25 wt-%, preferably from about 0.5-10 wt-%. The concentration in a semi-solid or solid composition such as a gel or a powder will be about 0.01-15 wt-%, preferably about 0.5-2.5 wt-%.
  • In general, however, a suitable dose will be in the range of from about 0.05 to 50 gm per day; or preferably from about 0.05 to about 500 mg per kilogram body weight of the recipient per day, preferably in the range of 0.1 to 200 mg/kg/day.
  • The compound is conveniently administered in unit dosage form; for example, containing 0.1-20 g, conveniently 1-7.5 g, or more conveniently, 2-5 g of active ingredient per unit dosage form.
  • The total daily dose, i.e., of about 0.05-50 g, may be administered for about 1-4 months, or longer, as needed.
  • Ideally, the active ingredient should be administered to achieve peak plasma concentrations of the active compound of from about 0.5 to about 75 μM, preferably, about 1 to 50 μM, most preferably, about 2 to about 30 μM. This may be achieved, for example, by the intravenous injection of a 0.05 to 5% solution of the active ingredient, optionally in saline, or orally administered as a bolus containing about 1-100 mg of the active ingredient. Desirable blood levels may be maintained by continuous infusion to provide about 0.01-5.0 mg/kg/hr or by intermittent infusions containing about 0.4-15 mg/kg of the active ingredient(s).
  • The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day. The sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations; such as multiple inhalations from an insufflator or by application of a plurality of drops into the eye.
    • Example 1 Preparation of 1,3-Bis(4-bromobutyroyl)propane (VII)
  • Figure US20100022643A2-20100128-C00005
  • A 500 ml round-bottomed flask was charged with 19.4 ml of pyridine in 150 ml of dichloromethane (CH2Cl2), and stirring initiated as the solution was cooled to 0° C. Propane-1,3-diol (8.0 g) was added, and stirring continued. A mixture of 26.4 ml of 4-bromobutyroyl chloride in 75 ml CH2Cl2 was added dropwise to the stirred pyridine/CH2Cl2 and stirring continued for 5 hrs at 0° C. The reaction mixture was washed with 300 ml H2O, the organic layer was isolated and washed with 100 ml in HCl aq, 100 ml NaCl aq and dried over MgSO4 (anhydrous). The solvents were removed in vacuo to yield the product (VII) as a translucent low viscosity oil.
    • Example 2 Preparation of 1,3-Bis(4-acetoxybutyroyl)propane (VIII)
  • Figure US20100022643A2-20100128-C00006
  • A solution of 20.6 g potassium acetate and 3.49 g potassium iodide in 306 ml acetic anhydride was stirred and the product (VII) of Ex. 1 added. The reaction mixture was refluxed with stirring for 12-16 hrs, then cooled to 25° C. and diluted with 100 ml EtOAc. The reaction mixture was filtered, and the filtrate concentrated in vacuo. Ethyl acetate (400 ml) was added and the resultant solution was washed with 2×200 ml of 50% aq. NaHCl3. The organic layer was isolated, dried (MgSO4 an.), filtered and concentrated in vacuo. Purification by flash chromatography yielded product (VIII) in 66.3% yield as a viscous light yellow oil (93% pure).
    • REFERENCES
    • Bedard et al., Clin. Neuropharmacol., 12(1) 29 (1989)
    • Broughton and Mamelak, Can. J. Neur. Sci., 7, 23 (1980)
    • Gallimberti et al., Lancet, 2(8666), 787 (1989)
    • Gallimberti et al., Alcohol Clin. Exp. Res., 16(4) 673 (1992)
    • Gallimberti et al., Neuropsychopharmacology, 9(1) 77 (1993)
    • Gallimberti et al., Eur. Arch. Psychiatry Clin. Neurosci., 244(3) 113 (1994)
    • Gerra et al., Int. Clin. Psychopharmacol., 9(3) 211 (1994)
    • Gessa et al., Clin. Neuropharmacol., 15 Suppl. 1 Pt. A 303A (1992)
    • Grove-White and Kelman, Br. J. Anaesth, 43(2) 110 (1971)
    • Hasenbos and Gielen, Anaesthesia, 40(10) 977 (1985)
    • Hoes et al., Encephale, 6(1) 93 (1980)
    • Laborit, Laboratoire d' Eutonologie, Hopital Boucicaut Paris 15 France, 1973
    • Ladinsky et al., Naunyn Schmiedebergs Arch Pharmacol., 322(1) 42 (1983)
    • Lammers et al., Sleep, 16(3) 216 (1993)
    • Lapierre et al., Sleep, 13(1) 24 (1990)
    • Lee, Biochem Med., 17(3) 284 (1977)
    • Mamelak et al., Lancet, 2(7824) 328 (1973)
    • Mamelak et al., Biol. Psychiatry, 12(2) 273 (1977)
    • Mamelak et al., Biol. Psychiatry, 14(5) 821 (1979)
    • Oyama et al., Br. J. Anaesth., 42(12) 1105 (1970)
    • Palatini et al., Eur. J. Clin. Pharmacol., 45(4) 353 (1993)
    • Scharf et al., J. Clin. Psychiatry, 46(6) 222 (1985)
    • Scharf et al., Am. Fam. Phys., 143 (1988)
    • Scrima et al., Sleep, 13(6) 479 (1990)
    • Series et al., Am. Rev. Respir. Dis., 145(6) 1378 (1992)
    • Scharf et al., J. Clin Psychiatry, 46(6) 222 (1985)
    • Snead and Morley, Brain Res., 227(4) 579 (1981)
    • Stock et al., Naunyn Schmiedebergs Arch Pharmacol., 278(4) 347 (1973)
    • Strong, Lancet, 1(8389) 1304 (1984)
    • Yamada et al., Electroencephalogr. Clin. Neurophysiol., 22(6) 558 (1967)
  • All publications, patents, and patent documents are incorporated by reference herein, as though individually incorporated by reference. The invention has been described with reference to various specific and preferred embodiments and techniques. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the invention.

Claims (17)

1. A compound of the formula (II):

(R′O(CH2)3CO2)m(ROC(O)(CH2)3OC(O))q—(X)—(Y)n-(Z)n—(CO2(CH2)3CO2R)p(O2C(CH2)3OR′)k  (II)
wherein R′ is H or a hydroxyl-protecting group, R is H, (C1-C4)alkyl or benzyl, X and Z are each residues of a hydroxy group-containing amino acid or a bis(carboxy)amino acid, Y is a moiety covalently linking X and Z, n is 0-1, m and k are 0 to the number of available hydroxy groups on the amino acids X and Z; q and p are 0 to the number of available CO2 groups on amino acids X and Z, with the proviso that both m and q and both p and k are not zero, or a pharmaceutically acceptable salt thereof.
2. A compound of the formula (III):
Figure US20100022643A2-20100128-C00007
wherein R1 is H or a hydroxyl-protecting group, R is H, (C1-C4)alkyl or benzyl, X is a residue of a hydroxy group-containing amino acids, Z is the residue of a hydroxy group-containing amino acid or a bis(carboxy) group-containing amino acid, Y is a moiety covalently linking X and Z, n is 0-1, m is 1 to the number of available hydroxy groups in amino acid X, p is 1 to the number of available CO2 groups on the amino acid X or Z, or a pharmaceutically acceptable salt thereof.
3. The compound of claim 1 wherein each of m, q, p and k is 1.
4. The compound of claim 1 wherein m and k are 0, and q and p are 1.
5. The compound of claim 1 wherein n=0, m=0 and k=0 and X is glutamic acid, aspartic acid or tyrosine.
6. The compound of claim 2 wherein m=p=1, n is 0 and X is tyrosine, threonine, or serine.
7. The compound of claim 2 wherein m=n=p=1 and Y is C(O)CH2CH2C(O) or C(O)CH═CH(CO).
8. A compound of formula (IV):
Figure US20100022643A2-20100128-C00008
wherein L and L′ are individually H, (C1-C6)alkyl or a hydroxyl protecting group or an organic moiety comprising at least one fatty alcohol, fatty ester or analog thereof, wherein at least one of L and L′ is said moiety.
9. The compound of claim 8 wherein at least one of L′ or L is -(A)(Y)(Z)n, wherein A is (C1-C6)alkyl, Y is H, OH N(R1)(R2)(R3) or [—O(PO3 −)-AN(R1)(R2)(R3), wherein R1, R2 and R3 are each (C1-C4)alkyl or R1 and R2 together with N are a (C5-C7)heterocyclic ring, optionally substituted with 1 or 2 N(R3), S, non-peroxide O or a combination thereof, n is 1-2 and Z is YR, wherein Y is O, S, NH, N(CH3), NHC(O) or OC(O) and R is (C8-C22)alkyl, optionally substituted with 1-2 double bonds, or a pharmaceutically acceptable salt thereof, with the proviso that when one of L or L′ is 1,3-dihexadecanoylprop-2-yl, the other is not H.
10. The compound of claim 9 wherein L′ is -(A)(Y)(Z)n and L is H, (C1-C6)alkyl or a hydroxyl protecting group.
11. The compound of claim 9 or 10 wherein Y is OC(O).
12. The compound of claim 8 wherein R is (C10-C22)alkyl.
13. The compound of claim 9 or 10 wherein Y is —O(PO3—)CH2CH2N(CH3)3 +.
14. The compound of claim 9 or 10 wherein (A)(Y)(Z)n is —CH[CH2Y][CH2Z].
15. A method for treating a mammal afflicted with a condition or pathology amenable to treatment by gamma-hydroxy butyrate (GHB) comprising administering to said mammal an effective amount of a compound of formula (II):

(R′O(CH2)3CO2)m(ROC(O)(CH2)3OC(O))q—(X)—(Y)n-(Z)n—(CO2(CH2)3CO2R)p(O2C(CH2)3OR′)k  (II)
wherein R′ is H or a hydroxyl-protecting group, R is H, (C1-C4)alkyl or benzyl, X and Z are each residues of a hydroxy group-containing amino acid or a bis(carboxy)amino acid, Y is a moiety covalently linking X and Z, n is 0-1, m and k are 0 to the number of available hydroxy groups on the amino acids X and Z; q and p are 0 to the number of available CO2 groups on amino acids X and Z, with the proviso that both m and q and both p and k are not zero, or a pharmaceutically acceptable salt thereof.
16. A method for treating a mammal afflicted with a condition or pathology amenable to treatment by gamma-hydroxy butyrate (GHB) comprising administering to said mammal an effective amount of a compound of formula (III):
Figure US20100022643A2-20100128-C00009
wherein R1 is H or a hydroxyl-protecting group, R is H, (C1-C4)alkyl or benzyl, X is a residue of a hydroxy group-containing amino acids, Z is the residue of a hydroxy group-containing amino acid or a bis(carboxy) group-containing amino acid, Y is a moiety covalently linking X and Z, n is 0-1, m is 1 to the number of available hydroxy groups in amino acid X, p is 1 to the number of available CO2 groups on the amino acid X or Z, or a pharmaceutically acceptable salt thereof.
17. A method for treating a mammal afflicted with a condition or pathology amenable to treatment by gamma-hydroxy butyrate (GHB) comprising administering to said mammal an effective amount of a compound of formula (IV):
Figure US20100022643A2-20100128-C00010
wherein L and L′ are individually H, (C1-C6)alkyl or a hydroxyl protecting group or an organic moiety comprising at least one fatty alcohol, fatty ester or analog thereof, wherein at least one of L and L′ is said moiety.
US12/465,069 2000-09-22 2009-05-13 Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers Expired - Fee Related US8778301B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/465,069 US8778301B2 (en) 2000-09-22 2009-05-13 Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers
US13/897,748 US20130324759A1 (en) 2000-09-22 2013-05-20 Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23472000P 2000-09-22 2000-09-22
US10/381,224 US7015200B2 (en) 2000-09-22 2001-09-21 Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers
PCT/US2001/029569 WO2002024715A2 (en) 2000-09-22 2001-09-21 Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers
US11/183,482 US7572605B2 (en) 2000-09-22 2005-07-18 Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers
US12/465,069 US8778301B2 (en) 2000-09-22 2009-05-13 Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
PCT/US2001/029569 Division WO2002024715A2 (en) 2000-09-22 2001-09-21 Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers
US11/183,482 Division US7572605B2 (en) 2000-09-22 2005-07-18 Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers
US10381224 Division 2005-07-18

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/897,748 Continuation US20130324759A1 (en) 2000-09-22 2013-05-20 Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers

Publications (3)

Publication Number Publication Date
US20090215890A1 US20090215890A1 (en) 2009-08-27
US20100022643A2 true US20100022643A2 (en) 2010-01-28
US8778301B2 US8778301B2 (en) 2014-07-15

Family

ID=22882520

Family Applications (4)

Application Number Title Priority Date Filing Date
US10/381,224 Expired - Lifetime US7015200B2 (en) 2000-09-22 2001-09-21 Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers
US11/183,482 Expired - Lifetime US7572605B2 (en) 2000-09-22 2005-07-18 Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers
US12/465,069 Expired - Fee Related US8778301B2 (en) 2000-09-22 2009-05-13 Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers
US13/897,748 Abandoned US20130324759A1 (en) 2000-09-22 2013-05-20 Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US10/381,224 Expired - Lifetime US7015200B2 (en) 2000-09-22 2001-09-21 Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers
US11/183,482 Expired - Lifetime US7572605B2 (en) 2000-09-22 2005-07-18 Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/897,748 Abandoned US20130324759A1 (en) 2000-09-22 2013-05-20 Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers

Country Status (7)

Country Link
US (4) US7015200B2 (en)
EP (1) EP1325014B1 (en)
JP (2) JP2004509900A (en)
AU (1) AU2001291173A1 (en)
CA (1) CA2423358C (en)
ES (1) ES2383673T3 (en)
WO (1) WO2002024715A2 (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925087B2 (en) 2000-09-15 2018-03-27 Bruder Healthcare Company, Llc Wound and therapy compress and dressing
US10105259B2 (en) 2000-09-15 2018-10-23 Bruder Healthcare Company, Llc Wound and therapy compress and dressing
WO2002022060A1 (en) 2000-09-15 2002-03-21 Bruder Healthcare Company Wound and therapy compress and dressing
US7015200B2 (en) 2000-09-22 2006-03-21 Orphan Medical, Inc. Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers
DK2526996T3 (en) * 2002-12-20 2019-12-02 Xeris Pharmaceuticals Inc Formulation for intracutaneous injection
US8133881B2 (en) 2003-01-13 2012-03-13 Shire Llc Carbohydrate conjugates to prevent abuse of controlled substances
EP1594513B1 (en) * 2003-01-13 2011-08-10 Shire LLC Carbohydrate conjugates to prevent abuse of controlled substances
JP2008512386A (en) * 2004-09-07 2008-04-24 オーファン メディカル，インコーポレイティド Improved GHB composition
US8193211B2 (en) * 2004-09-30 2012-06-05 Supernus Pharmaceuticals, Inc. Controlled release compositions of gamma-hydroxybutyrate
EP1809286A4 (en) * 2004-11-10 2010-09-01 Univ Columbia Method for treatment of movement disorders
US20120142618A1 (en) * 2007-02-13 2012-06-07 Btg International Limited Ketogenic saccharides
US8771735B2 (en) * 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
SI2421808T1 (en) 2009-04-23 2013-12-31 Concert Pharmaceuticals Inc. 4-hydroxybutyric acid analogs
US20120076865A1 (en) 2010-03-24 2012-03-29 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
KR101976218B1 (en) * 2011-02-14 2019-05-07 콘서트 파마슈티컬즈, 인크. 4-hydroxybutyric acid deuterated analogs
ES2774932T3 (en) 2012-11-14 2020-07-23 Cj Cheiljedang Corp Production of 4-hydroxybutyrate salts using bio-based raw materials
US8591922B1 (en) 2012-12-14 2013-11-26 Jazz Pharmacuticals, Inc. Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
WO2014143139A1 (en) 2013-03-15 2014-09-18 Bruder Healthcare Company Wound and therapy compress and dressing
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
CA2999367C (en) 2015-09-23 2023-09-26 Xw Laboratories Inc. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
UY37341A (en) 2016-07-22 2017-11-30 Flamel Ireland Ltd FORMULATIONS OF GAMMA-MODIFIED RELEASE HYDROXIBUTIRATE WITH IMPROVED PHARMACOCINETICS
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11000498B2 (en) 2016-07-22 2021-05-11 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
USD871598S1 (en) 2016-11-30 2019-12-31 Bruder Healthcare Company, Llc Therapeutic eye mask
USD844795S1 (en) 2016-11-30 2019-04-02 Bruder Healthcare Company, Llc Therapeutic eye mask
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US20200114015A1 (en) * 2017-04-11 2020-04-16 John K. Thottathil Novel Alpha-Hydroxy Carboxylic Acid And Derivatives And Other GRAS- Based Prodrugs Of Gamma-Hydroxybutyrate (GHB) And Uses Thereof
WO2019126215A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
JP2021506984A (en) 2017-12-18 2021-02-22 トリス・フアルマ・インコーポレーテツド Release-regulated drug powder composition comprising a gastric retention RAFT formation system with trigger pulse drug release
WO2019126214A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release
KR20210094513A (en) 2018-11-19 2021-07-29 재즈 파마슈티칼즈 아일랜드 리미티드 Alcohol-Resistant Drug Formulations
CA3127871A1 (en) 2019-03-01 2020-09-10 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
AU2020414694A1 (en) 2019-12-24 2022-08-18 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate (GHB) dosing
TW202139986A (en) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 Methods of treating idiopathic hypersomnia
US11896573B2 (en) 2020-07-24 2024-02-13 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
TW202228665A (en) 2020-10-05 2022-08-01 凱瑞康寧生技股份有限公司 Modified release compositions of a gamma-hydroxybutyric acid derivative
WO2022076824A1 (en) 2020-10-08 2022-04-14 Jazz Pharmaceuticals Ireland Limited Sodium oxybate to treat idiopathic hypersomnia
AU2021362222A1 (en) 2020-10-16 2023-06-01 Jazz Pharmaceuticals Ireland Limited Treatment methods using ghb
JP2024511991A (en) 2021-03-19 2024-03-18 エックスダブリューファーマ リミテッド Pharmacokinetics of combined release formulations of gamma-hydroxybutyric acid derivatives
WO2023062018A1 (en) 2021-10-11 2023-04-20 Jazz Pharmaceuticals Ireland Limited Method of administering oxybate
WO2023135150A1 (en) 2022-01-11 2023-07-20 Jazz Pharmaceuticals Ireland Limited Method of administering oxybate
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599355A (en) * 1984-02-10 1986-07-08 University Of Toronto - Innovations Foundation Treatment of sleep disorders
US4738985A (en) * 1986-03-19 1988-04-19 The University Of Toronto Innovations Foundations Pharmaceutical composition and treatment
US4755619A (en) * 1985-04-01 1988-07-05 National Research Development Corporation Pharmaceutical compositions
US5753708A (en) * 1991-04-29 1998-05-19 Koehler; Gernot Derivatives of 4-hydroxybutyric acid
US20050250848A1 (en) * 2000-09-22 2005-11-10 Orphan Medical, Inc. Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2226398A1 (en) * 1972-05-31 1973-12-13 Boehringer Sohn Ingelheim NEW HEART GLYCOSIDES AND METHODS FOR THEIR PRODUCTION
DE2702687A1 (en) * 1977-01-24 1978-07-27 Boehringer Sohn Ingelheim 3'-Acyl-altromethylosyl-bufatrienolide derivs. - used as orally resorbable cardiotonic agents
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
IT1238344B (en) * 1989-10-20 1993-07-13 Sigma Tau Ind Farmaceuti ESTERS OF L-CARNITINE WITH GAMMA-HYDROXYBUTIRRIC ACID AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT FOR THE INHIBITION OF NEURONAL DEGENERATION AND IN THE TREATMENT OF COMA
IT1240760B (en) * 1990-02-12 1993-12-17 Sigma Tau Ind Farmaceuti ACYL-L-CARNITINE ESTERS WITH GAMMA-HYDROXYBUTIRRIC ACID AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM FOR THE INHIBITION OF NEURONAL DEGENERATION AND IN THE TREATMENT OF COMA.
DE4026265A1 (en) 1990-08-20 1992-02-27 Boehringer Mannheim Gmbh NEW PHOSPHOLIPID DERIVATIVES OF NUCLEOSIDES, THEIR PRODUCTION AND THEIR USE AS ANTIVIRAL MEDICINAL PRODUCTS
GB9112212D0 (en) 1991-06-06 1991-07-24 Gregoriadis Gregory Pharmaceutical compositions
IT1261485B (en) 1993-06-24 1996-05-23 Sigma Tau Ind Farmaceuti USE OF ACIL L-CARNITINE RANGE-HYDROXYBUTIRRATE FOR THE TREATMENT OF DRUG ADDICTION.
JP2746079B2 (en) * 1993-09-07 1998-04-28 正和薬品株式会社 Blood glucose elevation inhibitor and lipid metabolism improver
SE502990C2 (en) * 1993-11-22 1996-03-04 Perstorp Ab Use of an inositol trisphosphate ester for the preparation of an analgesic drug
SE502989C2 (en) * 1993-11-22 1996-03-04 Perstorp Ab Use of an inositol trisphosphate ester for drug preparation
SE503122C2 (en) * 1993-11-22 1996-03-25 Perstorp Ab Use of an inositol trisphosphate ester for the treatment of inflammatory conditions
CA2283642C (en) * 1997-03-17 2012-05-15 Btg International Limited Therapeutic compositions
US5990162A (en) 1997-08-29 1999-11-23 Orphan Medical, Inc. Method for treatment of fibromyalgia and chronic fatigue syndrome
ATE292965T1 (en) * 1999-09-14 2005-04-15 Tepha Inc THERAPEUTIC USE OF POLYMERS CONTAINING GAMMA-HYDROXYBUTYRATE
US7686215B2 (en) 2005-05-21 2010-03-30 Apple Inc. Techniques and systems for supporting podcasting
US9405855B2 (en) 2014-03-27 2016-08-02 Sap Ag Processing diff-queries on property graphs

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599355A (en) * 1984-02-10 1986-07-08 University Of Toronto - Innovations Foundation Treatment of sleep disorders
US4755619A (en) * 1985-04-01 1988-07-05 National Research Development Corporation Pharmaceutical compositions
US4738985A (en) * 1986-03-19 1988-04-19 The University Of Toronto Innovations Foundations Pharmaceutical composition and treatment
US5753708A (en) * 1991-04-29 1998-05-19 Koehler; Gernot Derivatives of 4-hydroxybutyric acid
US20050250848A1 (en) * 2000-09-22 2005-11-10 Orphan Medical, Inc. Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers
US7015200B2 (en) * 2000-09-22 2006-03-21 Orphan Medical, Inc. Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers
US20130324759A1 (en) * 2000-09-22 2013-12-05 Orphan Medical, Inc. Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers

Also Published As

Publication number Publication date
EP1325014B1 (en) 2012-05-23
US20090215890A1 (en) 2009-08-27
CA2423358A1 (en) 2002-03-28
ES2383673T3 (en) 2012-06-25
US20130324759A1 (en) 2013-12-05
US20040092455A1 (en) 2004-05-13
EP1325014A2 (en) 2003-07-09
US7572605B2 (en) 2009-08-11
US8778301B2 (en) 2014-07-15
WO2002024715A3 (en) 2003-05-08
JP2004509900A (en) 2004-04-02
JP2012246312A (en) 2012-12-13
US7015200B2 (en) 2006-03-21
AU2001291173A1 (en) 2002-04-02
US20050250848A1 (en) 2005-11-10
WO2002024715A2 (en) 2002-03-28
CA2423358C (en) 2011-05-17

Similar Documents

Publication Publication Date Title
US8778301B2 (en) Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers
RU2141963C1 (en) Glycosides, methods for synthesis thereof, method of increasing biological accessibility of biologically-active material, and method of affecting living organism by biologically-active material
CA1340475C (en) Dopamine analog amide
US7553820B2 (en) Mevalonic acid derivatives
US5519007A (en) Lysosphingolipid derivatives
AU2006241176A1 (en) TRPV1 agonist compounds and methods for making and using the same
WO1996005209A9 (en) Sialic acid/fucose based medicaments
US20210299079A1 (en) Monomethyl fumarate-carrier conjugates and methods of their use
US5359128A (en) Malic acid derivatives and compositions for the treatment of psoriasis
FR2554346A1 (en) ASSEMBLY AND METHOD FOR THE ADMINISTRATION OF GANGLIOSIDES AND THEIR DERIVATIVES BY INHALATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
ES2750596T3 (en) Beta-glycolipids for use as adjuvants
US6020373A (en) Chelate derivatives as protectors against tissue injury
EP0410883B1 (en) Di-lysogangliosides derivatives
US7304039B2 (en) Glucose-based compounds with affinity to P-selectin
CN1651397A (en) Menthol derivative containing fatty acid and preparation containing said derivative
ES2254159T3 (en) BIOPRECURSORS OF A RETINOIC DERIVATIVE AND PHARMACEUTICAL AND / OR COSMETIC COMPOSITIONS.
AU2008200719B2 (en) Geranyl compounds
CA1228295A (en) Kit or device and method for administering gangliosides and derivatives thereof by inhalation and pharmaceutical composition suitable thereof
BRPI0216272B1 (en) MEVALONIC ACID DERIVATIVES, ANTITUMORAL AGENT, PHARMACEUTICAL COMPOSITION, AND USE OF A MEVALONIC ACID DERIVATIVE

Legal Events

Date Code Title Description
AS Assignment

Owner name: SILICON VALLEY BANK,CALIFORNIA

Free format text: SECURITY AGREEMENT;ASSIGNOR:JPI COMMERCIAL, LLC;REEL/FRAME:024611/0538

Effective date: 20100630

Owner name: SILICON VALLEY BANK, CALIFORNIA

Free format text: SECURITY AGREEMENT;ASSIGNOR:JPI COMMERCIAL, LLC;REEL/FRAME:024611/0538

Effective date: 20100630

AS Assignment

Owner name: JPI COMMERCIAL, LLC, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SILICON VALLEY BANK;REEL/FRAME:027505/0569

Effective date: 20111227

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCF Information on status: patent grant

Free format text: PATENTED CASE

CC Certificate of correction
AS Assignment

Owner name: JAZZ PHARMACEUTICALS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ORPHAN MEDICAL, LLC;REEL/FRAME:040282/0878

Effective date: 20161031

Owner name: JAZZ PHARMACEUTICALS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:JPI COMMERCIAL, LLC;REEL/FRAME:040282/0819

Effective date: 20161031

FEPP Fee payment procedure

Free format text: SURCHARGE FOR LATE PAYMENT, LARGE ENTITY (ORIGINAL EVENT CODE: M1554)

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551)

Year of fee payment: 4

AS Assignment

Owner name: U.S. BANK NATIONAL ASSOCIATION, NEW YORK

Free format text: SECURITY AGREEMENT;ASSIGNORS:CAVION, INC.;CELATOR PHARMACEUTICALS, INC.;JAZZ PHARMACEUTICALS IRELAND LIMITED;AND OTHERS;REEL/FRAME:056151/0010

Effective date: 20210505

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20220715